NUDT14

Summary

NUDT14 (nudix hydrolase 14, HGNC:20141) is a protein-coding gene on chromosome 14q32.33, encoding Uridine diphosphate glucose pyrophosphatase NUDT14 (O95848). Hydrolyzes UDP-glucose to glucose 1-phosphate and UMP and ADP-ribose to ribose 5-phosphate and AMP.

The protein encoded by this gene is a member of the Nudix hydrolase family. Nudix hydrolases eliminate potentially toxic nucleotide metabolites from the cell and regulate the concentrations and availability of many different nucleotide substrates, cofactors, and signaling molecules. This enzyme contains a Nudix hydrolase domain and is a UDPG pyrophosphatase that hydrolyzes UDPG to produce glucose 1-phosphate and UMP. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 256281 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 47 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_177533

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20141
Approved symbol	NUDT14
Name	nudix hydrolase 14
Location	14q32.33
Locus type	gene with protein product
Status	Approved
Aliases	UGPP
Ensembl gene	ENSG00000183828
Ensembl biotype	protein_coding
OMIM	609219
Entrez	256281

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 5 protein_coding, 3 retained_intron, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000339418, ENST00000392568, ENST00000546553, ENST00000550002, ENST00000550912, ENST00000551024, ENST00000859494, ENST00000859495, ENST00000859496, ENST00000943460

RefSeq mRNA: 2 — MANE Select: NM_177533 NM_001318380, NM_177533

CCDS: CCDS10000

Canonical transcript exons

ENST00000392568 — 5 exons

Exon	Start	End
ENSE00001512396	105172939	105173261
ENSE00002421624	105181129	105181312
ENSE00003518704	105176963	105177027
ENSE00003634253	105176534	105176771
ENSE00003658186	105177692	105177735

Expression profiles

Bgee: expression breadth ubiquitous, 221 present calls, max score 97.02.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.4082 / max 96.0688, expressed in 1777 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
145179	18.0005	1774
145178	0.4077	238

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adenohypophysis	UBERON:0002196	97.02	gold quality
pituitary gland	UBERON:0000007	96.30	gold quality
right uterine tube	UBERON:0001302	95.63	gold quality
anterior cingulate cortex	UBERON:0009835	95.18	gold quality
metanephros cortex	UBERON:0010533	95.05	gold quality
body of pancreas	UBERON:0001150	94.74	gold quality
prefrontal cortex	UBERON:0000451	94.40	gold quality
right frontal lobe	UBERON:0002810	94.28	gold quality
right lobe of thyroid gland	UBERON:0001119	94.27	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.08	gold quality
apex of heart	UBERON:0002098	93.96	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.76	gold quality
mucosa of transverse colon	UBERON:0004991	93.46	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.42	gold quality
amygdala	UBERON:0001876	93.37	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.09	gold quality
left lobe of thyroid gland	UBERON:0001120	92.96	gold quality
cortex of kidney	UBERON:0001225	92.70	gold quality
thyroid gland	UBERON:0002046	92.47	gold quality
frontal cortex	UBERON:0001870	92.14	gold quality
neocortex	UBERON:0001950	91.98	gold quality
spinal cord	UBERON:0002240	91.81	gold quality
nucleus accumbens	UBERON:0001882	91.80	gold quality
upper lobe of left lung	UBERON:0008952	91.79	gold quality
putamen	UBERON:0001874	91.61	gold quality
hypothalamus	UBERON:0001898	91.47	gold quality
minor salivary gland	UBERON:0001830	91.43	gold quality
caudate nucleus	UBERON:0001873	91.08	gold quality
upper lobe of lung	UBERON:0008948	90.94	gold quality
right testis	UBERON:0004534	90.93	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.98

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 1)

• the interaction between the RL13 protein and NUDT14 protein may be involved in human cytomegalovirus DNA replication. (PMID:26781650)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	nudt14	ENSDARG00000062335
mus_musculus	Nudt14	ENSMUSG00000002804
rattus_norvegicus	Nudt14	ENSRNOG00000014362
drosophila_melanogaster	CG42813	FBGN0261995
drosophila_melanogaster	CG42814	FBGN0261996
caenorhabditis_elegans		WBGENE00008238

Paralogs (1): NUDT5 (ENSG00000165609)

Protein

Protein identifiers

Uridine diphosphate glucose pyrophosphatase NUDT14 — O95848 (reviewed: O95848)

Alternative names: Nucleoside diphosphate-linked moiety X motif 14

All UniProt accessions (2): O95848, F8VU44

UniProt curated annotations — full annotation on UniProt →

Function. Hydrolyzes UDP-glucose to glucose 1-phosphate and UMP and ADP-ribose to ribose 5-phosphate and AMP. The physiological substrate is probably UDP-glucose. Poor activity on other substrates such as ADP-glucose, CDP-glucose, GDP-glucose and GDP-mannose.

Subunit / interactions. Homodimer.

Subcellular location. Cytoplasm.

Similarity. Belongs to the Nudix hydrolase family.

RefSeq proteins (2): NP_001305309, NP_803877* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000086	NUDIX_hydrolase_dom	Domain
IPR004385	NDP_pyrophosphatase	Family
IPR015797	NUDIX_hydrolase-like_dom_sf	Homologous_superfamily

Enzyme classification (BRENDA):

• EC 3.6.1.45 — UDP-sugar diphosphatase (BRENDA: 13 organisms, 29 substrates, 10 inhibitors, 27 Km, 8 kcat entries)

Substrate kinetics (BRENDA)

11 substrates with measured Km, best-characterized 11. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
UDP-GLUCOSE	0.0096–0.1755	10
UDP-D-GLUCOSE	0.002–5.9	6
ADP-D-RIBOSE	0.3	1
AMP	0.0012	1
CDP-D-GLUCOSE	0.33	1
GDP-D-GLUCOSE	0.11	1
MGATP2-	0.25	1
MGUTP2-	1	1
NAD+	0.0053	1
NADH	0.007	1
NMN	0.0111	1

UniProt features (26 total): strand 12, helix 8, turn 3, chain 1, domain 1, short sequence motif 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
8OTV	X-RAY DIFFRACTION	1.82
9HBM	X-RAY DIFFRACTION	1.83
9GZV	X-RAY DIFFRACTION	1.95
9GEM	X-RAY DIFFRACTION	2.02
3Q91	X-RAY DIFFRACTION	2.7
9H6P	X-RAY DIFFRACTION	3.16

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95848-F1	94.78	0.88

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-480985	Synthesis of dolichyl-phosphate-glucose

MSigDB gene sets: 90 (showing top): GOBP_PROTEIN_N_LINKED_GLYCOSYLATION, GOZGIT_ESR1_TARGETS_DN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, LIAO_METASTASIS, chr14q32, GOBP_GLYCOPROTEIN_METABOLIC_PROCESS, GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, KARLSSON_TGFB1_TARGETS_DN, BRUINS_UVC_RESPONSE_LATE

GO Biological Process (3): nucleoside phosphate metabolic process (GO:0006753), obsolete protein N-linked glycosylation via asparagine (GO:0018279), ribose phosphate metabolic process (GO:0019693)

GO Molecular Function (7): UDP-sugar diphosphatase activity (GO:0008768), identical protein binding (GO:0042802), metal ion binding (GO:0046872), ADP-ribose diphosphatase activity (GO:0047631), protein binding (GO:0005515), hydrolase activity (GO:0016787), hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides (GO:0016818)

GO Cellular Component (2): cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Synthesis of substrates in N-glycan biosythesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
organophosphate metabolic process	2
pyrophosphatase activity	2
cellular anatomical structure	2
nucleobase-containing small molecule metabolic process	1
carbohydrate derivative metabolic process	1
protein binding	1
cation binding	1
binding	1
catalytic activity	1
hydrolase activity, acting on acid anhydrides	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1080 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NUDT14	NUDT12	Q9BQG2	790
NUDT14	NUDT5	Q9UKK9	775
NUDT14	NUDT22	Q9BRQ3	774
NUDT14	NUDT18	Q6ZVK8	743
NUDT14	NUDT9	Q9BW91	721
NUDT14	NUDT17	P0C025	718
NUDT14	NUDT15	Q9NV35	709
NUDT14	NUDT2	P50583	666
NUDT14	NUDT1	P36639	620
NUDT14	NUDT4B	A0A024RBG1	570
NUDT14	NUDT19	A8MXV4	567
NUDT14	NAXE	Q8NCW5	559
NUDT14	NUDT3	O95989	554
NUDT14	NUDT6	P53370	512
NUDT14	TEX22	C9J3V5	507

IntAct

49 interactions, top by confidence:

A	B	Type	Score
NUDT14	NUDT14	psi-mi:“MI:0915”(physical association)	0.740
LNX1	NUDT14	psi-mi:“MI:0915”(physical association)	0.720
NIF3L1	NUDT14	psi-mi:“MI:0915”(physical association)	0.720
NUDT14	LNX1	psi-mi:“MI:0915”(physical association)	0.720
NUDT14	NIF3L1	psi-mi:“MI:0915”(physical association)	0.720
NUDT14	NTAQ1	psi-mi:“MI:0915”(physical association)	0.670
NTAQ1	NUDT14	psi-mi:“MI:0915”(physical association)	0.670
REL	NUDT14	psi-mi:“MI:0915”(physical association)	0.560
NUDT14	ZCCHC10	psi-mi:“MI:0915”(physical association)	0.560
ZCCHC10	NUDT14	psi-mi:“MI:0915”(physical association)	0.560
NUDT14	REL	psi-mi:“MI:0915”(physical association)	0.560
NUDT14	TEPSIN	psi-mi:“MI:0915”(physical association)	0.560
NUDT14	TERF2IP	psi-mi:“MI:0915”(physical association)	0.510
NUDT14	LNX2	psi-mi:“MI:0915”(physical association)	0.490
LNX2	NUDT14	psi-mi:“MI:0915”(physical association)	0.490
AHNAK2	NUDT14	psi-mi:“MI:0915”(physical association)	0.400
GNL3L	NUDT14	psi-mi:“MI:0915”(physical association)	0.400
SEPTIN4	NUDT14	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (21): NUDT14 (Two-hybrid), NUDT14 (Two-hybrid), NUDT14 (Two-hybrid), NUDT14 (Two-hybrid), NUDT14 (Two-hybrid), NUDT14 (Two-hybrid), LNX2 (Two-hybrid), NUDT14 (Two-hybrid), NUDT14 (Two-hybrid), NUDT14 (Two-hybrid), NIF3L1 (Two-hybrid), NUDT14 (Affinity Capture-MS), NUDT14 (Affinity Capture-MS), NUDT14 (Affinity Capture-MS), NUDT14 (Affinity Capture-MS)

ESM2 similar proteins: A4FV98, A5D7B1, A5PK51, A6QLN9, A8MUP2, D3ZVU9, O15527, O35595, O75078, O95848, P57775, Q05B60, Q06643, Q14728, Q14CX5, Q1LZB9, Q27HK4, Q2T9T5, Q2TBS1, Q3UGX3, Q4R3I0, Q4V892, Q58CT4, Q5E9H2, Q5RCI5, Q5SUV1, Q5TM22, Q642A6, Q6IA17, Q6PCB0, Q6XQN6, Q862Z7, Q8N8L6, Q8R2R5, Q8R2Z5, Q8R366, Q8WUG5, Q95JH0, Q95JH2, Q969P0

Diamond homologs: A1ADX2, A1JL31, A4TMK5, A4WD46, A6TC90, A7FG78, A7ML00, A7ZPR0, A8A2V7, A8ADC6, A8GHJ1, A9MHR4, A9N308, B1IWJ3, B1JSJ3, B1LNB6, B1XAD8, O95848, P37128, P44684, P54570, Q05B60, Q0T250, Q0TF11, Q1CK00, Q1R8R1, Q31Y24, Q32DA4, Q3YZ86, Q57LN3, Q5PCQ1, Q668I3, Q6D8X4, Q74SF4, Q7CQ25, Q83K58, Q8FF87, Q8KP10, Q8XBE7, Q8XG64

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1383 predictions. Top by Δscore:

Variant	Effect	Δscore
14:105181124:CTCA:C	donor_loss	1.0000
14:105181125:TCA:T	donor_loss	1.0000
14:105181126:CACC:C	donor_loss	1.0000
14:105181127:A:AT	donor_loss	1.0000
14:105181128:C:CA	donor_loss	1.0000
14:105181128:CCTGG:C	donor_gain	1.0000
14:105173460:C:A	donor_gain	0.9900
14:105173605:C:CT	acceptor_gain	0.9900
14:105173606:A:T	acceptor_gain	0.9900
14:105176529:CTCA:C	donor_loss	0.9900
14:105176530:TCACC:T	donor_loss	0.9900
14:105176531:CACC:C	donor_loss	0.9900
14:105176533:C:A	donor_loss	0.9900
14:105176612:T:TA	donor_gain	0.9900
14:105176767:CACAG:C	acceptor_gain	0.9900
14:105176769:CAG:C	acceptor_gain	0.9900
14:105176999:G:T	acceptor_gain	0.9900
14:105177026:CG:C	acceptor_gain	0.9900
14:105177688:TCACC:T	donor_loss	0.9900
14:105177689:CA:C	donor_loss	0.9900
14:105177690:ACCT:A	donor_loss	0.9900
14:105177731:CCATT:C	acceptor_gain	0.9900
14:105177732:CATT:C	acceptor_gain	0.9900
14:105177732:CATTC:C	acceptor_gain	0.9900
14:105177734:TT:T	acceptor_gain	0.9900
14:105177736:C:CC	acceptor_gain	0.9900
14:105181127:A:AC	donor_gain	0.9900
14:105181128:C:CC	donor_gain	0.9900
14:105173258:AGACC:A	acceptor_loss	0.9800
14:105173259:GACCT:G	acceptor_loss	0.9800

AlphaMissense

1409 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:105176970:G:C	F61L	0.979
14:105176970:G:T	F61L	0.979
14:105176972:A:G	F61L	0.979
14:105176971:A:G	F61S	0.977
14:105173222:G:C	F156L	0.970
14:105173222:G:T	F156L	0.970
14:105173224:A:G	F156L	0.970
14:105173223:A:G	F156S	0.956
14:105176606:G:T	A119D	0.949
14:105176971:A:C	F61C	0.945
14:105173090:C:A	K200N	0.941
14:105173090:C:G	K200N	0.941
14:105177027:G:C	S42R	0.941
14:105177027:G:T	S42R	0.941
14:105177693:T:G	S42R	0.941
14:105173058:A:G	F211S	0.939
14:105176656:C:A	E102D	0.931
14:105176656:C:G	E102D	0.931
14:105173070:C:T	G207D	0.929
14:105173071:C:G	G207R	0.926
14:105176766:A:C	Y66D	0.923
14:105177016:A:T	L46H	0.922
14:105177006:G:C	N49K	0.919
14:105177006:G:T	N49K	0.919
14:105176968:C:G	R62P	0.914
14:105176651:C:T	C104Y	0.909
14:105176652:A:G	C104R	0.908
14:105176546:A:T	V139D	0.906
14:105176650:A:C	C104W	0.905
14:105176649:C:G	A105P	0.904

dbSNP variants (sampled 300 via entrez): RS1000114505 (14:105178666 T>G), RS1000389644 (14:105182984 A>G), RS1000737353 (14:105176839 C>A,G,T), RS1000762877 (14:105173426 C>A,T), RS1000858220 (14:105180933 C>T), RS1001015122 (14:105175978 C>G,T), RS1001104853 (14:105177193 G>A), RS1001336280 (14:105181490 G>A), RS1001412461 (14:105182759 C>T), RS1001494665 (14:105176458 A>C,G), RS1001642208 (14:105176287 C>T), RS1001787333 (14:105182361 G>A), RS1001831648 (14:105175298 G>A,T), RS1001969009 (14:105175135 G>A), RS1002142092 (14:105182524 G>A,C,T)

Disease associations

OMIM: gene MIM:609219 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST010703_198	Brain morphology (MOSTest)	1.000000e-11
GCST90002385_40	High light scatter reticulocyte count	6.000000e-19
GCST90002386_589	High light scatter reticulocyte percentage of red cells	5.000000e-18
GCST90002387_4	Immature fraction of reticulocytes	3.000000e-11
GCST90002398_228	Neutrophil count	1.000000e-12
GCST90002405_379	Reticulocyte count	1.000000e-16
GCST90002406_381	Reticulocyte fraction of red cells	5.000000e-16
GCST90002407_584	White blood cell count	5.000000e-12

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement
EFO:0007986	reticulocyte count
EFO:0004833	neutrophil count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105943 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 7,994 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1873475	IBRUTINIB	4	7,994

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

6 potent at pChembl≥5 of 6 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.79	IC50	162	nM	CHEMBL5527860
6.58	IC50	263	nM	CHEMBL5549952
6.29	IC50	519	nM	CHEMBL1242204
6.00	IC50	990	nM	IBRUTINIB
5.79	IC50	1640	nM	CHEMBL5549782
5.43	IC50	3720	nM	CHEMBL5561533

PubChem BioAssay actives

6 with measured affinity, of 12 total; 6 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-(1-methylpiperidin-4-yl)-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine	2070375: Antagonist activity at N-terminal his6-tagged human recombinant NUDT14 (1 to 222 residues) expressed in Escherichia coli Rosetta (DE3) using ADP as substrate incubated for 1 hr by luminescence based microplate reader analysis	ic50	0.1620	uM
1-methyl-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine	2070375: Antagonist activity at N-terminal his6-tagged human recombinant NUDT14 (1 to 222 residues) expressed in Escherichia coli Rosetta (DE3) using ADP as substrate incubated for 1 hr by luminescence based microplate reader analysis	ic50	0.2630	uM
3-(4-phenoxyphenyl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine	2070375: Antagonist activity at N-terminal his6-tagged human recombinant NUDT14 (1 to 222 residues) expressed in Escherichia coli Rosetta (DE3) using ADP as substrate incubated for 1 hr by luminescence based microplate reader analysis	ic50	0.5190	uM
Ibrutinib	2070375: Antagonist activity at N-terminal his6-tagged human recombinant NUDT14 (1 to 222 residues) expressed in Escherichia coli Rosetta (DE3) using ADP as substrate incubated for 1 hr by luminescence based microplate reader analysis	ic50	0.9900	uM
N-[[4-[4-amino-1-(1-methylpiperidin-4-yl)pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]methyl]prop-2-enamide	2070375: Antagonist activity at N-terminal his6-tagged human recombinant NUDT14 (1 to 222 residues) expressed in Escherichia coli Rosetta (DE3) using ADP as substrate incubated for 1 hr by luminescence based microplate reader analysis	ic50	1.6400	uM
1-[5-[4-amino-1-(1-methylpiperidin-4-yl)pyrazolo[3,4-d]pyrimidin-3-yl]-3,6-dihydro-2H-pyridin-1-yl]prop-2-en-1-one	2070375: Antagonist activity at N-terminal his6-tagged human recombinant NUDT14 (1 to 222 residues) expressed in Escherichia coli Rosetta (DE3) using ADP as substrate incubated for 1 hr by luminescence based microplate reader analysis	ic50	3.7200	uM

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases expression	3
bisphenol A	increases expression, affects cotreatment, decreases expression	2
Cisplatin	affects expression, affects cotreatment, increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Particulate Matter	affects cotreatment, increases expression, decreases expression, increases abundance	2
tris(2-butoxyethyl) phosphate	affects expression	1
sodium arsenite	increases expression	1
nickel sulfate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
bisphenol S	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Decitabine	affects expression	1
Air Pollutants	decreases expression, increases abundance	1
Ethanol	affects cotreatment, increases abundance, increases expression	1
Dexamethasone	affects cotreatment, decreases expression, increases expression	1
Diazinon	increases methylation	1
Gasoline	increases expression, affects cotreatment, increases abundance	1
Indomethacin	affects cotreatment, decreases expression, increases expression	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, increases abundance, increases expression	1
Quercetin	increases expression	1
Smoke	decreases expression	1
Valproic Acid	decreases expression, increases methylation	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression, increases expression	1
Asbestos, Crocidolite	increases expression	1
Acrylamide	decreases expression	1

ChEMBL screening assays

4 unique, capped per target: 4 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4008388	Binding	Inhibition of human His-tagged NUDT14 expressed in bacterial expression system after 1 hr by malachite green reagent based assay	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1. — J Med Chem

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1I6	HAP1 NUDT14 (-) 1	Cancer cell line	Male
CVCL_D1I7	HAP1 NUDT14 (-) 2	Cancer cell line	Male
CVCL_D1I8	HAP1 NUDT14 (-) 3	Cancer cell line	Male
CVCL_D1I9	HAP1 NUDT14 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.